Predicting the biological activities through QSAR analysis and docking-based scoring

Methods in Molecular Biology

Volumn 914, Issue , 2012, Pages 271-284

  Vilar, Santiago ^a   Costanzi, Stefano ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Comparative molecular field analysis (CoMFA); Comparative molecular similarity index analysis (CoMSIA); G protein coupled receptors (GPCRs); Ligand based drug discovery; Molecular Docking; Multiple linear regression (MLR); Partial least square (PLS) regression; Quantitative structure activity relationships (QSAR); Structure based drug discovery

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; G PROTEIN COUPLED RECEPTOR;

ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CONSENSUS; CRYSTAL STRUCTURE; MOLECULAR DOCKING; PARTIAL LEAST SQUARES REGRESSION; PHYSICAL CHEMISTRY; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 84934443969     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-23-6_16     Document Type: Article

References (53)

1. Congreve M, Marshall F (2010) The impact of GPCR structures on pharmacology and structure-based drug design. Br J Pharmacol 159:986-996
2. Vilar S, Cozza G, Moro S (2008) Medicinal Chemistry and the Molecular Operating Environment (MOE): Application of QSAR and Molecular Docking to Drug Discovery. Curr Top Med Chem 8:1555-1572
3. Costanzi S, Tikhonova IG, Harden TK, Jacobson KA (2009) Ligand and structurebased methodologies for the prediction of the activity of G protein-coupled receptor ligands. J Comput Aided Mol Des 23:747-754
4. Pierce KL, Premont RT, Lefkowitz RJ (2002) Seven-transmembrane receptors. Nat Rev Mol Cell Biol 3:639-650
5. Vilar S, Karpiak J, Costanzi S (2010) Ligand and structure-based models for the prediction of ligand-receptor affinities and virtual screenings: Development and application to the b 2 -adrenergic receptor. J Comput Chem 31:707-720
6. Potemkin V, Grishina M (2008) Principles for 3D/4D QSAR classification of drugs. Drug Discov Today 13:952-959
7. Estrada E (2008) How the parts organize in the whole? A top-down view of molecular descriptors and properties for QSAR and drug design. Mini Rev Med Chem 8:213-221
8. Cramer RD, Patterson DE, Bunce JD (1988) Comparative Molecular-Field Analysis (CoMFA).1. Effect of Shape on Binding of Steroids to Carrier Proteins. J Am Chem Soc 110:5959-5967
9. Klebe G, Abraham U, Mietzner T (1994) Molecular Similarity Indexes in A Comparative-Analysis (CoMSIA) of Drug Molecules to Correlate and Predict Their Biological-Activity. J Med Chem 37:4130-4146
10. Wold S, Albano C, Dunn WJ, Esbensen K, Hellberg S, Johansson E et al (1984) Modeling data tables by principal components and PLSclass patterns and quantitative predictive relations. Analusis 12:477-485
11. Geladi P, Kowalski BR (1986) Partial leastsquares regression: a tutorial. Anal Chim Acta 185:1-17
12. Moro S, Bacilieri M, Ferrari C, Spalluto G (2005) Autocorrelation of molecular electrostatic potential surface properties combined with partial least squares analysis as alternative attractive tool to generate ligand-based 3D-QSARs. Curr Drug Discov Technol 2:13-21
13. Moro S, Bacilieri M, Cacciari B, Spalluto G (2005) Autocorrelation of molecular electrostatic potential surface properties combined with partial least squares analysis as new strategy for the prediction of the activity of human A 3 adenosine receptor antagonists. J Med Chem 48:5698-5704
14. Pastor M, Cruciani G, McLay I, Pickett S, Clementi S (2000) GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors. J Med Chem 43:3233-3243
15. Benedetti P, Mannhold R, Cruciani G, Ottaviani G (2004) GRIND/ALMOND investigations on CysLT1 receptor antagonists of the quinolinyl(bridged)aryl type. Bioorg Med Chem 12:3607-3617
16. Costanzi S, Siegel J, Tikhonova IG, Jacobson KA (2009) Rhodopsin and the others: a historical perspective on structural studies of G protein-coupled receptor. Curr Pharm Des 15:3994-4002
17. Hanson MA, Stevens RC (2009) Discovery of new GPCR biology: one receptor structure at a time. Structure 17:8-14
18. Costanzi S (2008) On the applicability of GPCR homology models to computer-aided drug discovery: a comparison between in silico and crystal structures of the beta2-adrenergic receptor. J Med Chem 51:2907-2914
19. Michino M., Abola E., GPCR Dock 2008 participants, Brooks C.L. 3rd
20. Dixon J.S., Moult J., Stevens R.C. (2009) Community-wide assessment of GPCR structure modelling and ligand docking: GPCR Dock 2008. Nat. Rev. Drug Discov. 8, 455-463
21. Costanzi S (2010) Modeling G protein-coupled receptors: a concrete possibility. Chimica Oggi-Chemistry Today 28:26-31
22. Chipot C, Rozanska X, Dixit SB (2005) Can free energy calculations be fast and accurate at the same time? Binding of low-affinity, non-peptide inhibitors to the SH2 domain of the src protein. J Comput Aided Mol Des 19:765-770
23. Foloppe N, Hubbard R (2006) Towards predictive ligand design with free-energy based computational methods? Curr Med Chem 13:3583-3608
24. Warren GL, Andrews C, Capelli AM, Clarke B, LaLonde J, Lambert MH et al (2006) A critical assessment of docking programs and scoring functions. J Med Chem 49:5912-5931
25. de Graaf C, Rognan D (2008) Selective structure-based virtual screening for full and partial agonists of the b 2-adrenergic receptor. J Med Chem 51:4978-4985
26. Reynolds KA, Katritch V, Abagyan R (2009) Identifying conformational changes of the b 2 -adrenoceptor that enable accurate prediction of ligand/receptor interactions and screening for GPCR modulators. J Comput Aided Mol Des 23:273-288
27. Katritch V, Rueda M, Lam PC, Yeager M, Abagyan R (2010) GPCR 3D homology models for ligand screening: lessons learned from blind predictions of adenosine A 2A receptor complex. Proteins 78:197-211
28. Bhattacharya S, Vaidehi N (2010) Computational mapping of the conformational transitions in agonist selective pathways of a G-protein coupled receptor. J Am Chem Soc 132:5205-5214
29. Vilar S, Ferino G, Sharangdhar SP, Berk B, Cavasotto CN, Costanzi S (2011) Dockingbased virtual screening for ligands of G proteincoupled receptors: not only crystal structures but also in silico models. J. Mol. Graph. Model 29, 614-623. Submitted for publication.
30. Topiol S, Sabio M (2008) Use of the X-ray structure of the b 2 -adrenergic receptor for drug discovery. Bioorg Med Chem Lett 18:1598-1602
31. Kolb P, Rosenbaum DM, Irwin JJ, Fung JJ, Kobilka BK, Shoichet BK (2009) Structurebased discovery of b 2 -adrenergic receptor ligands. Proc Natl Acad Sci USA 106: 6843-6848
32. Carlsson J, Yoo L, Gao ZG, Irwin JJ, Shoichet BK, Jacobson KA (2010) Structure-based discovery of A 2A adenosine receptor ligands. J Med Chem 53:3748-3755
33. Katritch V, Jaakola VP, Lane JR, Lin J, Ijzerman AP, Yeager M et al (2010) Structure-based discovery of novel chemotypes for adenosine A 2A receptor antagonists. J Med Chem 53: 1799-1809
34. Vaidehi N, Schlyer S, Trabanino RJ, Floriano WB, Abrol R, Sharma S et al (2006) Predictions of CCR1 chemokine receptor structure and BX 471 antagonist binding followed by experimental validation. J Biol Chem 281:27613-27620
35. Engel S, Skoumbourdis AP, Childress J, Neumann S, Deschamps JR, Thomas CJ et al (2008) A virtual screen for diverse ligands: Discovery of selective G protein-coupled receptor antagonists. J Am Chem Soc 130:5115-5123
36. Tikhonova IG, Sum CS, Neumann S, Engel S, Raaka BM, Costanzi S et al (2008) Discovery of novel agonists and antagonists of the free fatty acid receptor 1 (FFAR1) using virtual screening. J Med Chem 51:625-633
37. Cavasotto CN, Orry AJ, Murgolo NJ, Czarniecki MF, Kocsi SA et al (2008) Discovery of novel chemotypes to a G-protein-coupled receptor through ligand-steered homology modeling and structure-based virtual screening. J Med Chem 51:581-588
38. Bhattacharya S, Subramanian G, Hall S, Lin J, Laoui A, Vaidehi N (2010) Allosteric antagonist binding sites in class B GPCRs: corticotropin receptor 1. J Comput Aided Mol Des 24: 659-674
39. Dragon, Talete, SRL, www.talete.mi.it ; E-Dragon, Virtual Computational Chemistry Laboratory, www.vcclab.org .
40. The CODESSA PRO project, www.codessa-pro. com .
41. MOE, Chemical Computing Group, Inc., www.chemcomp.com .
42. Schrödinger, LLC, www.schrodinger.com .
43. ICM, MolSoft, LLC, www.molsoft.com .
44. SYBYL, Tripos, Inc., www.tripos.com .
45. GOLD, Cambridge Crystallographic Data Centre, www.ccdc.cam.ac.uk/ products/life- sciences/gold .
46. The R project for statistical computing, www.rproject. org .
47. STATISTICA, StatSoft, Inc., www.statsoft. com .
48. Okuno Y, Tamon A, Yabuuchi H, Niijima S, Minowa Y, Tonomura K et al (2008) GLIDA: GPCR-ligand database for chemical genomics drug discovery-database and tools update. Nucleic Acids Res 36:D907-D912
49. Costanzi S, Tikhonova IG, Ohno M, Roh EJ, Joshi BV, Colson AO et al (2007) P2Y 1 antagonists: Combining receptor-based modeling and QSAR for a quantitative prediction of the biological activity based on consensus scoring. J Med Chem 50:3229-3241
50. Golbraikh A, Tropsha A (2002) Beware of q2! J Mol Graph Model 20:269-276
51. Normolle D, Ruffin MT, Brenner D (2005) Design of early validation trials of biomarkers. Cancer Inform 1:25-31
52. Concato J, Peduzzi P, Holford TR, Feinstein AR (1995) Importance of events per independent variable in proportional hazards analysis I. Background, goals, and general strategy. J Clin Epidemiol 48:1495-1501
53. Hill T, Lewicki P (2006) In STATISTICS methods and applications. StatSoft, Tulsa, OK